GT Biopharma, Inc. (GTBP)
| Market Cap | 15.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.04M |
| Shares Out | 36.06M |
| EPS (ttm) | -2.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 843,048 |
| Open | 0.430 |
| Previous Close | 0.416 |
| Day's Range | 0.420 - 0.460 |
| 52-Week Range | 0.261 - 3.850 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product cand... [Read more]
Financial Performance
Financial StatementsNews
GT Biopharma Proxy statement: Proxy filing
GT Biopharma filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tu...
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing develop...
GT Biopharma Reports First Quarter 2026 Financial Results
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to expres...
GT Biopharma Quarterly report: Q1 2026
GT Biopharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
GT Biopharma Earnings release: Q1 2026
GT Biopharma released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
GT Biopharma doses first patient in GTB-5550 trial
GT Biopharma (GTBP) announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550, its B7-H3-targeted natural killer (NK) cell engager for solid tumors…
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalati...
GT Biopharma files to sell 9.72M shares of common stock for holders
16:57 EDT GT Biopharma (GTBP) files to sell 9.72M shares of common stock for holders
GT Biopharma Registration statement: Registration filing
GT Biopharma filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
A modular NK cell engager platform is advancing through clinical trials for blood cancers, solid tumors, and autoimmune diseases, with promising efficacy and a strong safety profile. The technology leverages camelid nanobody innovation and targets vast oncology and autoimmune markets.
GT Biopharma Slides: Corporate presentation
GT Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
GT Biopharma price target lowered to $3 from $8 at Roth Capital
Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on GT Biopharma (GTBP) to $3 from $8 and keeps a Buy rating on the shares. The firm is citing…
GT Biopharma price target lowered to $3 from $8 at Roth Capital
Roth Capital lowered the firm’s price target on GT Biopharma (GTBP) to $3 from $8 and keeps a Buy rating on the shares. As of January, GT Biopharma held pro…
GT Biopharma expects cash to fund operations through Q4 2026
Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026. “2026 looks to bring more significant milestones for…
GT Biopharma Reports Full Year 2025 Financial Results
Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5
GT Biopharma Earnings release: Q4 2025
GT Biopharma released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.
GT Biopharma Annual report: Q4 2025
GT Biopharma has published its Q4 2025 annual report on March 2, 2026.
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics b...
GT Biopharma announces FDA clearance of IND application for GTB-5550
GT Biopharma (GTBP) announced FDA clearance of its IND application for GTB-5550, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to initiate in mid-2026.
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, ...
GT Biopharma Registration statement: Registration Filing
GT Biopharma filed a registration statement on January 21, 2026, providing details about a securities offering with the SEC.
GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE
GT Biopharma (GTBP) announced the submission of an investigational new drug, IND, application to the U.S. Food and Drug Administration, FDA, in December 2025 for GTB-5550 TriKE, a B7-H3-targeted natur...
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cas...
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC , Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination ...